Bayer Secures Approval for Kerendia in Heart Failure Treatment

Bayer has announced that it has received regulatory approval from Indian authorities for its innovative drug, Kerendia, which is designed to treat heart failure. This medication, known generically as finerenone, was previously approved for the treatment of chronic kidney disease associated with type 2 diabetes.

Shweta Rai, Managing Director of Bayer's Pharmaceutical Division in India, stated, 'With the expansion of finerenone's indication, we are addressing types of heart failure that account for nearly half of all heart failure cases but have had limited proven treatment options.' This approval marks a significant development in the management of heart failure, which is a chronic condition characterised by the heart's inability to pump sufficient blood to meet the body's needs, resulting in symptoms such as fatigue, breathlessness, and fluid accumulation.

Heart failure is a major public health issue, with millions of people affected globally. Unlike a heart attack, which occurs suddenly, heart failure develops gradually over time. As a result, patients may experience worsening symptoms and a decline in quality of life.

The expansion of finerenone's indications to include heart failure represents Bayer's commitment to addressing significant health challenges in India, including cardiovascular disease and chronic kidney disease. The company aims to provide innovative solutions to improve patient outcomes in these areas.

Bayer's approval for Kerendia in heart failure treatment comes at a crucial time as healthcare providers seek new therapies to manage this prevalent condition. The approval is expected to offer healthcare professionals additional options in treating patients suffering from various types of heart failure, particularly those with limited treatment alternatives.

With the rising incidence of heart failure in India, driven by factors such as diabetes, hypertension, and an ageing population, the need for effective therapies has never been greater. Bayer's introduction of Kerendia into the market is anticipated to play a vital role in addressing the healthcare needs of patients with heart failure and improving their overall quality of life.